Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:22 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $66.4M (14.7% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2026 | Feb 25, 2025 | Feb 27, 2024 | Mar 13, 2023 | Mar 14, 2022 |
| Revenue | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M |
| Operating expenses | – | – | $160.6M | $88.5M | $69.2M |
| Research and development | $64.3M | $53.4M | $50.3M | $42.6M | $41.7M |
| Selling, general and administrative | $427.3M | $237.3M | $108.7M | $44.9M | $25.4M |
| Operating income | -$71.0M | -$120.6M | -$143.2M | -$62.7M | -$12.2M |
| Interest expense | $8.94M | $7.85M | $3.35M | $2.20M | – |
| Income tax | $2.06M | $0 | $0 | -$4.00K | $55.0K |
| Net income | -$66.4M | -$115.6M | -$135.9M | -$62.1M | -$13.8M |
| EPS, basic | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
| EPS, diluted | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
| Weighted shares, basic | 41.8M | 37.6M | 29.4M | 24.6M | 20.6M |
| Weighted shares, diluted | 41.8M | 37.6M | 29.4M | 24.6M | 20.6M |
| Margins and growth | |||||
| Operating margin | -15.7% | -65.9% | -820.5% | -242.9% | -21.3% |
| Net margin | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% |
| Revenue growth, year over year | +146.7% | +948.6% | −32.4% | −54.7% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2026 | Feb 25, 2025 | Feb 27, 2024 | Mar 13, 2023 | Mar 14, 2022 |
| Cash and equivalents | $183.6M | $94.8M | $224.9M | $71.7M | $171.3M |
| Short-term investments | $233.6M | $196.6M | $2.50M | $145.4M | $483.0K |
| Accounts receivable | $85.1M | $46.8M | $16.6M | – | – |
| Inventory | $4.37M | $2.62M | $3.11M | – | – |
| Total current assets | $522.8M | $356.7M | $256.1M | $225.4M | $176.0M |
| Property, plant and equipment | $11.7M | $2.31M | $1.47M | $957.0K | $755.0K |
| Intangible assets | $7.37M | $8.33M | $3.87M | – | – |
| Total assets | $562.2M | $377.0M | $265.5M | $227.9M | $178.9M |
| Accounts payable | $16.4M | – | – | – | – |
| Total current liabilities | $135.7M | $80.6M | $36.9M | $15.4M | $11.5M |
| Long-term debt | $72.4M | $71.8M | $29.8M | $19.4M | – |
| Total liabilities | $218.7M | $152.5M | $68.5M | $35.0M | $12.2M |
| Shareholders' equity | $343.4M | $224.5M | $197.0M | $192.9M | $166.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2026 | Feb 25, 2025 | Feb 27, 2024 | Mar 13, 2023 | Mar 14, 2022 |
| Operating cash flow | -$12.5M | -$83.0M | -$117.5M | -$49.0M | $3.75M |
| Capital expenditures | $9.86M | $1.57M | $1.50M | $506.0K | $586.0K |
| Free cash flow | -$22.3M | -$84.6M | -$119.0M | -$49.5M | $3.16M |
| Stock-based compensation | $41.7M | $27.8M | $19.8M | $13.5M | $8.46M |
| Investing cash flow | -$42.1M | -$199.2M | $140.6M | -$144.6M | -$586.0K |
| Financing cash flow | $143.4M | $154.7M | $130.2M | $94.0M | $21.0K |
| Net change in cash | $88.8M | -$127.6M | $153.3M | -$99.7M | $3.18M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 9.2% | 15.2% | 113.7% | 52.1% | 14.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 49.3M | +16.2% | SEC |
| Jul 30, 2026 | 43.9M | +4.0% | SEC |
| May 1, 2026 | 43.0M | +2.4% | SEC |
| Feb 17, 2026 | 42.6M | +10.9% | SEC |
| Oct 29, 2025 | 42.4M | +11.0% | SEC |
| Jul 31, 2025 | 42.2M | +11.0% | SEC |
| Apr 24, 2025 | 42.0M | +11.2% | SEC |
| Feb 19, 2025 | 38.4M | +12.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.